MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

被引：0

作者：

Wolf, Denise M. ^{[1
]}

Yau, Christina ^{[1
]}

Sanil, Ashish ^{[2
]}

Chien, Jo ^{[1
]}

Wallace, Anne ^{[3
]}

DeMichele, Angela ^{[4
]}

Kaplan, Hank ^{[5
]}

Yee, Doug ^{[6
]}

Isaacs, Claudine ^{[7
]}

Albain, Kathy ^{[8
]}

Viscuzi, Rebecca ^{[9
]}

Boughey, Judy ^{[10
]}

Moulder, Stacey ^{[11
]}

Chui, Steven ^{[12
]}

Khan, Qamar ^{[13
]}

Styblo, Toncred ^{[14
]}

Edmiston, Kirsten ^{[15
]}

Northfelt, Donald ^{[16
]}

Elias, Anthony ^{[17
]}

Haley, Barbara ^{[18
]}

Tripathy, Debu ^{[19
]}

Brown-Swigart, Lamorna ^{[1
]}

Flynn, Susan ^{[1
]}

Hirst, Gillian ^{[1
]}

Buxton, Meredith ^{[1
]}

Hylton, Nola ^{[1
]}

Paoloni, Melissa ^{[20
]}

Symmans, Fraser ^{[11
]}

Esserman, Laura ^{[1
]}

Berry, Don ^{[2
]}

Rugo, Hope ^{[1
]}

Olopade, Olufunmilayo I. ^{[21
]}

van 't Veer, Laura ^{[1
]}

机构：

[1] Univ Calif, Davis, CA USA

[2] Berry Consultants LLC, Austin, TX USA

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Swedish Canc Inst, Seattle, WA USA

[6] Univ Minnesota, Minneapolis, MN 55455 USA

[7] Georgetown Univ, Washington, DC 20057 USA

[8] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[9] Univ Arizona, Tucson, AZ 85721 USA

[10] Mayo Clin, Rochester, MN USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[13] Univ Kansas, Med Ctr, Lawrence, KS 66045 USA

[14] Emory Univ, Atlanta, GA 30322 USA

[15] Inova Hlth Syst, Washington, DC USA

[16] Mayo Clin, Rochester, MI USA

[17] Univ Colorado, Colorado Springs, CO USA

[18] Univ Texas, Houston, TX USA

[19] Univ So Calif, Los Angeles, CA 90089 USA

[20] QuantumLeap Healthcare, Los Angeles, CA USA

[21] Univ Chicago, Chicago, IL 60637 USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-06-25

引用

页数：2

共 50 条

[1] MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Yau, Christina
Wolf, Denise M.
Sanil, Ashish
Chien, Jo
Wallace, Anne
Boughey, Judy
Yee, Doug
Tripathy, Debu
DeMichele, Angela
Nanda, Rita
Chiu, Steven
Isaacs, Claudine
Albain, Kathy
Kaplan, Hank
Moulder, Stacey
Viscusi, Rebecca
Northfelt, Donald
Edmiston, Kirsten
Elias, Anthony
Styblo, Toncred
Haley, Barbara
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian L.
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, W. Fraser
Esserman, Laura
Berry, Don
Liu, Minetta C.
Park, John W.
van 't Veer, Laura
CANCER RESEARCH, 2015, 75
[2] DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Wolf, D. M.
Yau, C.
Sanil, A.
Glas, A.
Petricoin, C.
Wulfkuhle, J.
Brown-Swigart, L.
Hirst, G.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olapade, O.
van't Veer, L.
CANCER RESEARCH, 2017, 77
[3] MammaPrint High1/High2 risk class as a pre-specified biomarker of response to nine different targeted agents plus standard neoadjuvant therapy for ∼1000 breast cancer patients in the I-SPY 2 TRIAL
van't Veer, L. J.
Wolf, D.
Yau, C.
Glas, A.
Brown-Swigart, L.
Asare, S.
Hirst, G.
Hylton, N.
Symmans, F.
Berry, D.
Demichele, A.
Yee, D.
Esserman, L.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E15 - E15
[4] Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Buxton, Meredith
Paoloni, Melissa
Olopade, Olufunmilayo
De Michele, Angela
Symmans, Fraser
Rugo, Hope
Berry, Don
Esserman, Laura
van't Veer, Laura
CANCER RESEARCH, 2016, 76
[5] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
CANCER RESEARCH, 2013, 73
[6] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[7] Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Daemen, Anneleen
Heiser, Laura
Gray, Joe
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
DeMichele, Angela
Hylton, Nola
Symmans, Fraser
Yee, Doug
Paoloni, Melissa
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo
van't Veer, Laura
CANCER RESEARCH, 2015, 75
[8] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Park, John W.
Liu, Minetta C.
Yee, Douglas
DeMichele, Angela
van't Veer, Laura
Hylton, Nola
Symmans, Fraser
Buxton, Meredith B.
Chien, A. Jo
Wallace, Amy
Melisko, Michelle
Schwab, Richard
Boughey, Judy
Tripathy, Debashish
Kaplan, Hank
Nanda, Rita
Chui, Stephen
Albain, Kathy S.
Moulder, Stacy
Elias, Anthony
Lang, Julie E.
Edminston, Kirsten
Northfelt, Donald
Euhus, David
Khan, Qamar
Lyandres, Julia
Davis, Sarah E.
Yau, Christina
Sanil, Ashish
Esserman, Laura J.
Berry, Donald A.
CANCER RESEARCH, 2014, 74 (19)
[9] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
CANCER RESEARCH, 2016, 76
[10] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →